Bank of New York Mellon Corp Grows Holdings in Sage Therapeutics, Inc. (SAGE)

Bank of New York Mellon Corp raised its position in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) by 36.5% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,710,027 shares of the biopharmaceutical company’s stock after purchasing an additional 724,494 shares during the period. Bank of New York Mellon Corp owned approximately 7.22% of Sage Therapeutics worth $168,834,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SAGE. Principal Financial Group Inc. raised its position in Sage Therapeutics by 1.1% during the first quarter. Principal Financial Group Inc. now owns 5,623 shares of the biopharmaceutical company’s stock valued at $400,000 after purchasing an additional 62 shares in the last quarter. Teachers Advisors LLC increased its holdings in shares of Sage Therapeutics by 139.5% in the first quarter. Teachers Advisors LLC now owns 118,072 shares of the biopharmaceutical company’s stock worth $8,391,000 after buying an additional 68,776 shares during the period. Legal & General Group Plc increased its holdings in shares of Sage Therapeutics by 9.5% in the first quarter. Legal & General Group Plc now owns 10,748 shares of the biopharmaceutical company’s stock worth $755,000 after buying an additional 934 shares during the period. Schwab Charles Investment Management Inc. increased its holdings in shares of Sage Therapeutics by 1.2% in the first quarter. Schwab Charles Investment Management Inc. now owns 131,440 shares of the biopharmaceutical company’s stock worth $9,342,000 after buying an additional 1,593 shares during the period. Finally, AQR Capital Management LLC purchased a new position in shares of Sage Therapeutics in the first quarter worth about $1,170,000.



Shares of Sage Therapeutics, Inc. (NASDAQ SAGE) opened at $83.89 on Tuesday. Sage Therapeutics, Inc. has a 12-month low of $44.55 and a 12-month high of $99.80.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.98) by $0.01. The firm’s revenue for the quarter was up .0% on a year-over-year basis. equities analysts forecast that Sage Therapeutics, Inc. will post -7.38 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This article was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this article on another site, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this article can be viewed at https://ledgergazette.com/2017/11/21/bank-of-new-york-mellon-corp-grows-holdings-in-sage-therapeutics-inc-sage.html.

SAGE has been the topic of several analyst reports. J P Morgan Chase & Co decreased their price objective on Sage Therapeutics from $99.00 to $85.00 and set an “overweight” rating on the stock in a report on Tuesday, September 12th. Canaccord Genuity decreased their price objective on Sage Therapeutics from $110.00 to $81.00 and set a “buy” rating on the stock in a report on Tuesday, September 12th. Royal Bank Of Canada lifted their price objective on Sage Therapeutics from $117.00 to $120.00 in a report on Thursday, November 2nd. Needham & Company LLC decreased their price objective on Sage Therapeutics from $95.00 to $86.00 and set a “buy” rating on the stock in a report on Wednesday, September 13th. Finally, SunTrust Banks, Inc. reiterated a “buy” rating and issued a $82.00 price objective (down previously from $95.00) on shares of Sage Therapeutics in a report on Wednesday, September 13th. Three research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. Sage Therapeutics presently has an average rating of “Buy” and an average target price of $105.71.

Sage Therapeutics Company Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Institutional Ownership by Quarter for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply